Meeting
2021 Gastrointestinal Cancers Symposium
Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
Presenter
Thierry Andre, MD
Sorbonne Université and Hôpital Saint Antoine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Oral Abstract Session: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02715284
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 9)
DOI
10.1200/JCO.2021.39.3_suppl.9
Abstract #
9
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.
Speaker: Thierry Andre, MD
Videos & Slides
2024 ASCO Annual Meeting
Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.
Speaker: Wungki Park, MD, MS
Videos & Slides
2024 ASCO Annual Meeting
A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.
Speaker: Neil Howard Segal, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.
Speaker: Dan-yun Ruan, MD